QURE ALERT: FDA Reportedly Accuses uniQure of Pushing “Distorted” and “Manipulated” Data For “Failed” AMT-130 Drug Amid Pending Securities Class Action – Hagens Berman
uniQure N.V. - Ordinary Shares (QURE)
Last uniqure n.v. - ordinary shares earnings: 4/29 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
uniqure.com/investors-newsroom/overview.php
Company Research
Source: GlobeNewswire
SAN FRANCISCO, March 13, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) following an unprecedented public rebuke of the company by federal health officials. This investigation follows the filing of a securities class action lawsuit seeking to represent investors who purchased or otherwise acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025 (the “Class Period”). SUBMIT YOUR QURE LOSSES TO HBSS NOW Federal Officials Condemn uniQure in WSJ Report: “Company Lied” On March 5, 2026, The Wall Street Journal published “Federal Health Officials Attack Rare-Disease Drug, Say Company Lied,” reporting on unusual public criticism by officials at the Food and Drug Administration and Department of Health and Human Resources directed at uniQure N.V. (NASDAQ: QURE). According to the report, “[a] senior FDA official said in a call with reporters Thursday that the data from the
Show less
Read more
Impact Snapshot
Event Time:
QURE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QURE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QURE alerts
High impacting uniQure N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
QURE
News
- QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud LawsuitPR Newswire
- Kessler Topaz Meltzer & Check, LLP Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE); April 13, 2026, Lead Plaintiff DeadlineGlobeNewswire
- uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLCPR Newswire
- uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, DeadlinePR Newswire
- QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire
QURE
Earnings
- 11/10/25 - Miss
QURE
Sec Filings
- 3/9/26 - Form 4
- 3/9/26 - Form 3
- 3/6/26 - Form 4
- QURE's page on the SEC website